Skip to main content
. 2020 Nov 6;413(2):599–612. doi: 10.1007/s00216-020-03031-7

Fig. 2.

Fig. 2

Osimertinib serum concentrations obtained from two patients treated for EGFR-mutant metastatic lung adenocarcinoma